Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

New in the British Journal of Cancer: post hoc analysis of METIMMOX - high TMB or BRAF-V600E may identify nivolumab responders in MSS metastatic CRC.

1 Posts 1 Posters 0 Views

B This user is from outside of this forum
B This user is from outside of this forum
Benjamin P. Geisler

wrote last edited by

#1

New in the British Journal of Cancer: post hoc analysis of METIMMOX - high TMB or BRAF-V600E may identify nivolumab responders in MSS metastatic CRC.
Hypothesis-generating,
PFS only,
prognostic vs. predictive unresolved.
But a signal worth pursuing. 🧬
https://rdcu.be/e5kDi
1 Reply Last reply
1
0
I med-mastodon.com shared this topic

Log in to reply